Pharmacological agents currently in clinical trials for disorders in neurogastroenterology
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Self-citationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 1×
“Thus, rifaximin, a nonabsorbable antibiotic, was associated with adequate relief that was even documented for 10 weeks after cessation of treatment (34); however, stool consistency and number and urgency of bowel movements were not improved.”
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576 · cited 1×
“There is considerable evidence supporting prucalopride’s pharma-codynamic effects, safety, and efficacy in chronic constipation (72); it is approved in most countries, but not in the United States.”
Self-citationWEDLAKE, L., A’HERN, R., RUSSELL, D., THOMAS, K., WALTERS, J. R. F., & ANDREYEV, H. J. N. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04081.x · Cited by 435
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub3 · Cited by 389
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283 · cited 1×
“Similarly, a meta-analysis that included five clinical trials demonstrated global IBS symptom and bloating improvement, but no significant effect on bowel function (35).”
Duboc, H., Rainteau, D., Rajca, S., Humbert, L., Farabos, D., Maubert, M., Grondin, V., Jouet, P., Bouhassira, D., Seksik, P., et al. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01893.x · Cited by 256 · cited 1×
“33, 69).”
Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms
Bredenoord, A. J., Chial, H. J., Camilleri, M., Mullan, B. P., & Murray, J. A. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00130-7 · Cited by 243
Self-citationShin, A., Camilleri, M., Vijayvargiya, P., Busciglio, I., Burton, D., Ryks, M., Rhoten, D., Lueke, A., Saenger, A., Girtman, A., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.020 · Cited by 192
Self-citationWong, B. S., Camilleri, M., McKinzie, S., Burton, D., Graffner, H., & Zinsmeister, A. R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.285 · Cited by 133 · cited 1×
“This drug accelerated colonic transit (77) and significantly increased stool frequency and improved constipation-related symptoms over 8 weeks of treatment in CIC patients (78).”
CORINALDESI, R., STANGHELLINI, V., CREMON, C., GARGANO, L., COGLIANDRO, R. F., DE GIORGIO, R., BARTESAGHI, G., CANOVI, B., & BARBARA, G. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04041.x · Cited by 131
Cinca, R., Chera, D., Gruss, H. ‐., & Halphen, M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12278 · Cited by 73
Tuteja, A. K., Fang, J. C., Al-Suqi, M., Stoddard, G. J., & Hale, D. C. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.694903 · Cited by 41 · cited 1×
“Mesalazine induced relief of pain and diarrhea in patients with these predominant symptoms in a third trial (58), but efficacy was not replicated in a recent small trial (59).”
Cited by
Wouters, M. M., Balemans, D., Van Wanrooy, S., Dooley, J., Cibert-Goton, V., Alpizar, Y. A., Valdez-Morales, E. E., Nasser, Y., Van Veldhoven, P. P., Vanbrabant, W., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.034 · Cited by 372
Gastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Elobixibat and its potential role in chronic idiopathic constipation
Acosta, A., & Camilleri, M. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14528269 · Cited by 91
“In addition to the approved drugs detailed above, others are in development: prokinetic 5-HT4 receptor agonists, such as velusetrag and naronapride; guanyl cyclase C receptor agonists, such as plecanatide; a bile acid (BA) (delayed-release chenodeoxycholic acid [CDCA]); an ileal BA transporter (IBAT) inhibitor (elobix…”
BackgroundSelf-citationCyclic AMP‐dependent positive feedback signaling pathways in the cortex contributes to visceral pain
Liu, S., Wang, X., Yue, J., Yang, L., Li, X., Hu, L., Lu, J., Song, Q., Zhang, K., Yang, Q., et al. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14903 · Cited by 30
Metadata
- Authors
- Camilleri, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-10-01
- Volume
- 123
- Issue
- 10
- Pages
- 4111-4120
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2035551063
- Cited by
- 32
- References
- 13
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.